AVITA Medical amends PermeaDerm agreements: higher revenue share, EU/UK/AU expansion option

AVITA Medical, Inc.

$500,000 fee gives AVITA right of first offer/refusal to expand exclusive PermeaDerm distribution to EU, UK, Australia.
Revenue share from PermeaDerm rises to 67% (sheet) and 80% (glove) from July 1, 2026; extra payments if gross margin >50% (sheet) or >35% (glove).
Growth minimums set: $1.0M in 2026, then 20% annual growth to $2.0736M by 2030; prior minimums waived.
Stedical can sell in certain U.S. markets; AVITA supplies at cost +10%. For OUS (Asia) sales, price $200/carton + 10% manufacturing fee up to 1,600 cartons.
Milestone payments: AVITA pays $1M if total sales exceed $45M, and $1.5M if exceed $90M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.